Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Carcinoma

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Ovarian Cancer

Ovarian Epithelial Cancer

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Administration with anti-MESO CAR-T cells in the MESO-positive ovarian cancer patients

Retroviral vector-transduced autologous T cells to express anti-MESO CARs

anti-MESO CAR-T cells

Zhigang Zhang, M.D.

Jianwei Zhou, M.D.

The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen receptors (CARs) T cell therapy for relapsed and refractory epithelial ovarian cancer.

Primary Objectives

To determine the feasibility ad safety of anti-MESO CAR-T cells in treating patients with MESO-positive ovarian cancer.

Secondary Objectives

To access the efficacy of anti-MESO CAR-T cells in patients with ovarian cancer.

To determine in vivo dynamics and persistency of anti- MESO CAR-T cells.

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

Safety and Effectiveness of MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d d-4\~-2. Then anti- MESO CAR-T cells will be injected by a dose of 5×106/kg once at d1(rang from d1-3).

Autologous genetically modified anti- MESO CAR transduced T cells

anti- MESO CAR-T cells

Hui Zhao, doctor

Yincheng Teng, doctor

Hui Zhao

The goal of this clinical trial is to study the safety and feasibility of anti- Mesothelin Chimeric Antigen Receptor T-Cell (MESO CAR-T cells) therapy for Refractory-Relapsed Ovarian Cancer

Primary Objectives:

1. To determine the safety and feasibility of anti- MESO CAR-T cells therapy for Refractory-Relapsed Ovarian Cancer

Secondary Objectives:

1. To access the efficacy of anti- MESO CAR-T cells in patients with ovarian cancer.
2. To determine in vivo dynamics and persistency of anti- MESO CAR-T cells
3. To assess the quality of life in patients with ovarian cancer after treatment with anti- MESO CAR-T cells.

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

The Clinical Research of Fourth Generation CART-cell Therapy in Refractory-Relapsed Ovarian Cancer

Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.03

the highest concentration (Cmax) of anti-human MESO T cells in the peripheral blood after administration

the time to reach the highest concentration (Tmax) of anti-human MESO T cells in the peripheral blood after administration

the area under the curve of 30 days of anti-human MESO T cells in the peripheral blood after administration

Duration of Mesothelin-positive T cells in circulation

Overall response rate after administration

Progress Free Survival after administration

This QLQ-C15-PAL score consists of 15 questions; two multi-item functional scales (physical and emotional functioning), two multi-item symptom scales (fatigue and pain) together with five single-item symptom scales (nausea/vomiting, dyspnea, insomnia, appetite loss, constipation) and one final question referring to overall QOL. The physical functioning scale is based on three questions regarding walking, activities of daily living and time spent in bed or in a chair. The emotional functioning scale is based on two questions that ask about feeling tense or depressed. Patients rated each question on a Likert scale from 1 (not at all) to 4 (very much), with the exception of overall QOL, which was rated from 1 (very poor) to 7 (excellent)

Hrain Biotechnology Co., Ltd.

Shanghai 6th People's Hospital

professor

The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen receptors (CARs) T cell therapy for relapsed and refractory ovarian cancer.

Primary Objectives

1.To determine the feasibility ad safety of anti-MESO CAR-T cells in treating patients with MESO-positive ovarian cancer.

Secondary Objectives

1. To access the efficacy of anti-MESO CAR-T cells in patients with ovarian cancer.
2. To determine in vivo dynamics and persistency of anti- MESO CAR-T cells.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer	NCT03916679	Ovarian Cancer	anti-MESO CAR-T...	18 Years - 70 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer	NCT03814447	Ovarian Cancer	anti- MESO CAR-... Fludarabine Cyclophosphamid...	18 Years - 75 Years	Shanghai 6th People's Hospital
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer	NCT03799913	Ovarian Cancer	anti-MESO CAR-T... Fludarabine Cyclophosphamid...	18 Years - 70 Years	Zhejiang University
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer	NCT03799913	Ovarian Cancer	anti-MESO CAR-T... Fludarabine Cyclophosphamid...	18 Years - 70 Years	Zhejiang University

Spots Global Cancer Trial Database for meso

Every month we try and update this database with for meso cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for meso

Every month we try and update this database with for meso cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for meso cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.